Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Morris

Showing results (281-290 of 303) with videos related to

Pageof 31
Sort By:
Science Translational Medicine|September 20, 2019
Immune correlates of the Thai RV144 HIV vaccine regimen in South AfricaGlenda E Gray, Ying Huang, Nicole Grunenberg, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Journal of Virology|July 29, 2011
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestorsMattia Bonsignori, Kwan-Ki Hwang, Xi Chen, et al.
Plos Pathogens|September 26, 2017
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationCecilia Rademeyer, Bette Korber, Michael S Seaman, et al.
Journal of Virology|April 26, 2013
Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen designLi-Hua Ping, Sarah B Joseph, Jeffrey A Anderson, et al.
Plos Pathogens|July 20, 2016
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationCecilia Rademeyer, Bette Korber, Michael S Seaman, et al.
Cell Host & Microbe|September 11, 2015
Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant VirusesM Anthony Moody, Feng Gao, Thaddeus C Gurley, et al.
Cell Reports|January 28, 2023
Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donorKelsey A Pilewski, Steven Wall, Simone I Richardson, et al.
Science Translational Medicine|March 17, 2017
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptideS Munir Alam, Baptiste Aussedat, Yusuf Vohra, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2024
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresMichal Juraska, Hongjun Bai, Allan C deCamp, et al.
Pageof 31

Showing results (281-290 of 303) with videos related to

Sort By:
Pageof 31
Science Translational Medicine|September 20, 2019
Immune correlates of the Thai RV144 HIV vaccine regimen in South AfricaGlenda E Gray, Ying Huang, Nicole Grunenberg, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Journal of Virology|July 29, 2011
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestorsMattia Bonsignori, Kwan-Ki Hwang, Xi Chen, et al.
Plos Pathogens|September 26, 2017
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationCecilia Rademeyer, Bette Korber, Michael S Seaman, et al.
Journal of Virology|April 26, 2013
Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen designLi-Hua Ping, Sarah B Joseph, Jeffrey A Anderson, et al.
Plos Pathogens|July 20, 2016
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationCecilia Rademeyer, Bette Korber, Michael S Seaman, et al.
Cell Host & Microbe|September 11, 2015
Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant VirusesM Anthony Moody, Feng Gao, Thaddeus C Gurley, et al.
Cell Reports|January 28, 2023
Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donorKelsey A Pilewski, Steven Wall, Simone I Richardson, et al.
Science Translational Medicine|March 17, 2017
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptideS Munir Alam, Baptiste Aussedat, Yusuf Vohra, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2024
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresMichal Juraska, Hongjun Bai, Allan C deCamp, et al.
Pageof 31